Welcome : Guest

Rising Incidence of Psychiatric and Neurodegenerative Disorders Drive the Global CNS Therapeutics Market

Published: November 2017


  • Code: MCP-1835
  • Pages: 611
  • Tables: 96
  • Companies: 162


The global market for CNS Therapeutics is projected to reach US$145 billion by 2024, driven by the rapidly aging population and a parallel rise in Parkinsonís, Alzheimerís, pain manifestations, cerebrovascular disorders, stroke, seizures, cognitive and memory disorders. Other major factors driving growth include an encouraging global pipeline of late stage drugs; rising acceptance of new therapies and new classes of drugs; increased demand for combination therapies; growing use of generics; and launch of new Alzheimerís drugs including anti-amyloid proteins, cholinergic and nicotine receptor agonists, neuro protective drugs, vaccines and GABA receptor modulators. A key trend in the market is pharma companiesí efforts to restrategize CNS drug development, which still continues to cost significantly higher than development costs in other therapeutic areas. Increased use of contract research organization services; and predictive planning to prevent late stage drug failure are few of the strategies adopted to infuse vigor in the CNS drug development space. Asia-Pacific ranks as the fastest growing market over the analysis period led by factors such as changing social structures and increased risk of developing psychiatric disorders such as schizophrenia, sleep disorders, depression and anxiety; growing literacy rates, improved awareness and gradual reduction in the stigma associated with neurological disorders; and government policy led development of healthcare delivery systems. 

    Summary of Findings

  • Better Understanding of the Electrochemical Processes of the Brain and Development of Disease-Modifying Therapies to Drive Growth in the Antiepileptic Drugs Market
  • Ability to Offer Additive Benefits and Target Multiple Pathologic Processes Simultaneously Drive Demand for Combination CNS Therapies
  • Development of Neuro Protective Drugs & New Alzheimerís Drugs Engineered to Target Toxic Amyloid Proteins in the Brain to Support Long-Term Growth in the Market
  • Increase in CNS Prescriptions for Pain Manifestations and Psychiatric Disorders to Benefit Demand
  • Growing Focus on Healthcare Cost Containment and Rationalization Spurs Sales of Generic CNS Medications

    Timeline for Analysis

  • Market Estimates and Forecasts for 2016-2024
  • Historic Review 2011-2015

    Geographic Markets Analyzed

  • US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, Russia and Rest of Europe), Asia-Pacific (China, India and Rest of Asia-Pacific), Latin America (Brazil and Rest of Latin America), and Rest of World

    Market Segmentation & Classification

  • Product Groups:
    • Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Others


  • AbbVie Inc.
  • Alkermes Plc
  • Allergan, Plc
  • Amneal Pharmaceuticals, LLC
  • AstraZeneca Plc
  • BIAL Group


  • Review of Industry/Market Structure
  • Analysis of Trends & Drivers
  • Insights on Macro Market Scenarios
  • Market SWOT Analysis
  • Latent Demand Forecasts & Projections
  • Comprehensive Geographic Market Analysis
  • Presentation Ready Facts & Statistical Data Findings
  • Coverage of Major/Niche Players, Market Shares & Competition
  • Coverage of major Company/Technology/Product/Financial Stories
  • Extensive Product/Service/End-Use/Technology Coverage Where Applicable

Interested in our research, you can contact our 24/7 Research Support e-Desk at rsd@strategyr.com